BT

Biote CorpNASDAQ BTMD Stock Report

Last reporting period 30 Jun, 2024

Updated 19 Nov, 2024

Last price

Market cap $B

0.314

Micro

Exchange

XNAS - Nasdaq

BTMD Stock Analysis

BT

Uncovered

Biote Corp is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

44/100

Low score

Market cap $B

0.314

Dividend yield

Shares outstanding

9.273 B

biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. The company is headquartered in Irving, Texas. The company went IPO on 2021-03-02. The firm provides components to enable Biote-certified practitioners to establish, build, and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. Its Biote Method is a comprehensive, end-to-end practice-building platform that provides Biote-certified practitioners with components specifically developed for practitioners in the hormone optimization space, such as Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. The firm trains practitioners how to identify and treat early indicators of hormone-related aging conditions. The company also sells a complementary Biote-branded line of dietary supplements.

View Section: Eyestock Rating